Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PFE

Pfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for Income

Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options.

Barchart

Pfizer Stock: Analyst Estimates & Ratings

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Barchart

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Benzinga

What MEPs and Parliament’s parties want from the EU budget

Each political group is seeking to safeguard at least one flagship priority within the EU's long-term budget, and is prepared to defend it to the bitter end.

Euronews

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, can cause cancer.

Benzinga

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence (BCR) at high…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Wednesday’s Unusual Options Activity Reveals 3 Standout Long Straddle Plays

There were 37 unusually active options in Wednesday Trading that expire in 30 days. This DTE reveals three standout long straddle plays that provide a nice combination of time and cost, while allowing increased volatility to take its course.

Barchart

Patriots for Europe look to derail signature EU climate policy with key parliament file

The far-right Patriots for Europe are now a step closer to derail one of the EU’s flagship policy, the so-called Green Deal.

Euronews

Top 5 Undervalued Dividend Stocks With Strong Payout Potential

Seemingly undervalued dividend stocks, such as BAC, F, MO, VZ, and PFE, offer a rare combination of strong yields and attractive valuations.

MarketBeat

Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year historical average P/E ratio.

Barchart

Is Pfizer Stock Underperforming the S&P 500?

Pfizer has underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Polish far-right MEPs uncomfortable in Sovereign Nations group

The three Polish members of Europe of Sovereign Nations are unhappy with the group’s stance on Russia. But they will not leave it (for now).

Euronews

Do Wall Street Analysts Like Pfizer Stock?

Pfizer has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

This Dividend Stock Yields Nearly 8% and Trades at Depressed Valuations: Time to Buy?

Amid the continued decline in Pfizer stock, its dividend yield has risen to almost 8%. While the stock might not be a screaming buy, it now seems to have limited downside.

Barchart

What You Need to Know Ahead of Pfizer's Earnings Release

Pfizer will release its first-quarter earnings later this month, and analysts anticipate a double-digit profit dip.

Barchart

Huge Unusual Trading in Pfizer Put Options Signals Investors' Bearish Outlook

Large, unusual trading volume in Pfizer put options is accruing today, signaling a bearish outlook by institutional investors in PFE stock. This undoubtedly relates to the Chinese tariffs, and investors' concerns.

Barchart

How Is Pfizer's Stock Performance Compared to Other Pharmaceuticals Stocks?

Pfizer has underperformed the pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading.

StockNews.com

3 Gene Therapy Stocks With Game-Changing Potential

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, investing in gene therapy stocks like Pfizer (PFE), Sanofi (SNY), and Novartis AG (NVS) could be beneficial. Read on….

Barchart

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Barchart

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Barchart

Pfizer Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Pfizer trailing behind the broader market over the past year, Wall Street analysts remain moderately bullish about the stock's potential.

Barchart

This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.

For savvy investors, Pfizer could be an undervalued stock to buy here.

StockNews.com

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.